Search

Displaying results 1281 - 1290 of 3389 in total
  1. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacin...

    Categories: Tumor Necrosis Factor Receptor Blocking Activity
  2. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genit...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: AZITHROMYCIN HEC P 200/5ML
  3. Target

    Serotonin Receptors

    go.drugbank.com/bio_entities/BE0004862
    TargetHumans

    Receptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).

    Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: Serotonin receptor 1A, Serotonin receptor 1B
  4. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  5. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction

  6. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

    Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substrates
  7. Drug

    ATB-346

    go.drugbank.com/drugs/DB15377
    Investigational

    ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).

  8. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  9. Drug

    Navafenterol

    go.drugbank.com/drugs/DB19195
    Investigational

    Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

  10. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively